Precision Biologics for
Autoimmune Disease

1

Autoimmune Antibodies

Targeting  pathogenic antibodies

2

Autoimmune Antibodies

Glycan on pathogenic antibodies drives tissue damage effective function

3

Precision

Hydrolizes glycan on pathogenic antibodies stopping tissue damage

Differentiated MOA Provides Competitive Advantage to Current Modalities

Rapid Onset of Action

reduces reliance on prolonged steroid therapy.

Preservationof Total IgG Levels

maintains humoral immunity

Deeper Suppression of Autoantibodies

leads to enhanced efficacy and the ability to capture non-responders

Reduced Dosing Frequency

lowering overall treatment burden.

Highly Potent Molecule

Reduces DP volume and cost of goods

Leadership + team

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Renato Skerlj, PhD
Chief Executive Officer
Discovering and developing disease modifying small molecule drugs to treat genetically defined diseases.
Jean Chamoun, MD
Chief Medical Officer
Extensive experience in protein expression, protein purification and characterization, molecular biology, cell culture and protein engineering
Jennifer Visco, CPA
SVP, Finance & Operations
Executive skilled in Financial Planning & Analysis, Budgeting & Forecasting, Strategic Planning and more...
Scientific founders

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Jeffrey V. Ravetch, M.D, PhD
Founding Scientist
Dr. Ravetch, M.D., Ph.D., Theresa and Eugene Lang Professor, Rockefeller University; Head Leonard Wagner Laboratory of Molecular Genetics and Immunology.
Eric J. Sundberg, PhD
Founding Scientist
Dr. Sundenberg is an internationally recognized expert in antibody engineering, immune modulation, and protein–glycan interactions.
Diego E. Sastre, PhD
Founding Scientist
Dr. Diego is an Assistant Professor in the Department of Biochemistry at the Emory University School of Medicine, where he studies the molecular mechanisms underlying enzymes that modify antibodies.
investment Partners

Seed Round

Our latest NewCo, Rhapsogen, co-founded by Catalio Venture Partner Dr. Jeff Ravetch of Rockefeller University and Dr. Eric Sundberg of Emory University has officially launched, forging a new paradigm for the treatment of autoimmune diseases!

Matthew Hobson, Ph.D.
Principal
Matthew (Matt) Hobson, PhD is a Principal at Catalio Capital Management LP where he primarily covers investments in therapeutics and diagnostics for their venture and private credit strategies.
R. Jacob Vogelstein, PhD
Co-Founder & Managing Partner
Jacob Vogelstein is the Co-Founder & Managing Partner of Catalio Capital Management, LP. Jacob currently serves on the Boards of Iambic, Rhapsogen, Syndeio, Clasp, Nextpoint and Pheast.

Copyright ©

Rhapsogen. All rights reserved.

Rhapsogen is developing a best in class precision biologic for autoimmune disease with superior efficacy, safety and durability.